000301722 001__ 301722
000301722 005__ 20250601020903.0
000301722 0247_ $$2doi$$a10.1093/neuonc/noaf125
000301722 0247_ $$2pmid$$apmid:40424588
000301722 0247_ $$2ISSN$$a1522-8517
000301722 0247_ $$2ISSN$$a1523-5866
000301722 0247_ $$2altmetric$$aaltmetric:177512009
000301722 037__ $$aDKFZ-2025-01114
000301722 041__ $$aEnglish
000301722 082__ $$a610
000301722 1001_ $$00000-0003-4925-7600$$aDeng, Maximilian Y$$b0
000301722 245__ $$aPostoperative radiotherapy in subtotally-resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.
000301722 260__ $$aOxford$$bOxford Univ. Press$$c2025
000301722 3367_ $$2DRIVER$$aarticle
000301722 3367_ $$2DataCite$$aOutput Types/Journal article
000301722 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748603047_4403
000301722 3367_ $$2BibTeX$$aARTICLE
000301722 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301722 3367_ $$00$$2EndNote$$aJournal Article
000301722 500__ $$a#LA:B300# / epub
000301722 520__ $$aMeningiomas represent the most common primary intracranial tumors in adults, with WHO grade 1 typically associated with favorable outcomes following gross total resection (GTR).This retrospective study included patients with CNS WHO grade 1 meningioma and available DNA methylation profiles (n=210). Clinical tumor characteristics and treatment course (e.g., surgical resection, extent of resection, radiotherapy) were evaluated. Integrated Scores (InS) were calculated based on methylation family using the DKFZ brain tumor classifier, CNS WHO grading, and chromosomal losses, categorized as low, intermediate, or high. Survival analyses employed Kaplan-Meier and Cox regression methods, with local progression-free survival defined as primary endpoint.In newly diagnosed cases, GTR was associated with a 93.0% 3-year progression-free survival (PFS), compared to 69.3% following subtotal resection (STR). Stratification by IntS showed that patients in the IntS-low group had superior outcomes: 3-y PFS of 93.4 after GTR and 77.4% after STR. In contrast, patients with IntS-intermediate/high profiles showed significantly worse outcomes, with PFS of 85.9% after GTR and 40.0% after STR. Following tumor recurrence, particularly those with IntS-intermediate/high, postoperative radiotherapy (RT) after STR may improve 3-year PFS to 88.9%, compared to much lower PFS rates in newly diagnosed cases managed without adjuvant RT after STR (3-year PFS: 40.0%).Our findings highlight the combined impact of both the extent of resection (EoR) and molecular risk profile on prognosis in newly diagnosed cases. While conservative management is feasible in lower-risk primary cases, recurrent or higher-risk patients may benefit from early postoperative RT.
000301722 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000301722 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301722 650_7 $$2Other$$aWHO grade 1 meningioma
000301722 650_7 $$2Other$$aextent of resection
000301722 650_7 $$2Other$$aintegrated score
000301722 650_7 $$2Other$$amolecular diagnostics
000301722 7001_ $$aMaas, Sybren L N$$b1
000301722 7001_ $$aAnil, Günes$$b2
000301722 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b3$$udkfz
000301722 7001_ $$aLischalk, Jonathan$$b4
000301722 7001_ $$aZhao, Eric$$b5
000301722 7001_ $$aRauh, Sophie$$b6
000301722 7001_ $$aJessen, Inga$$b7
000301722 7001_ $$aEichkorn, Tanja$$b8
000301722 7001_ $$aRegnery, Sebastian$$b9
000301722 7001_ $$aBauer, Lukas$$b10
000301722 7001_ $$aHeld, Thomas$$b11
000301722 7001_ $$0P:(DE-HGF)0$$aHoegen-Sassmannshausen, Philipp$$b12
000301722 7001_ $$aSeidensaal, Katharina$$b13
000301722 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b14$$udkfz
000301722 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b15$$udkfz
000301722 7001_ $$0P:(DE-HGF)0$$aWick, Antje$$b16
000301722 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b17$$udkfz
000301722 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b18$$udkfz
000301722 7001_ $$aHerfarth, Klaus$$b19
000301722 7001_ $$aJungk, Christine$$b20
000301722 7001_ $$aKrieg, Sandro M$$b21
000301722 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b22$$udkfz
000301722 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b23$$eLast author$$udkfz
000301722 7001_ $$aKönig, Laila$$b24
000301722 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf125$$gp. noaf125$$pnn$$tNeuro-Oncology$$vnn$$x1522-8517$$y2025
000301722 909CO $$ooai:inrepo02.dkfz.de:301722$$pVDB
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000301722 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000301722 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000301722 9141_ $$y2025
000301722 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000301722 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000301722 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000301722 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000301722 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000301722 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000301722 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x2
000301722 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x3
000301722 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x4
000301722 980__ $$ajournal
000301722 980__ $$aVDB
000301722 980__ $$aI:(DE-He78)B300-20160331
000301722 980__ $$aI:(DE-He78)HD01-20160331
000301722 980__ $$aI:(DE-He78)E050-20160331
000301722 980__ $$aI:(DE-He78)B062-20160331
000301722 980__ $$aI:(DE-He78)B320-20160331
000301722 980__ $$aUNRESTRICTED